Hikma Could Consider Exit Strategy For Generics Business

Also Provides Update On CEO Search As Recruitment Process Continues

24 Jan 2023

Hikma says all options are on the table for its beleaguered generics business, with an immediate sale unlikely but the door open for a longer-term exit strategy. Meanwhile, the firm has also offered an update on recruitment for a new CEO.

Door Exit Dollar Sign Shadow — Hikma could consider exiting the generics business – but admits the timing might not be right to extract maximum value from the division • Source: Shutterstock

In candid comments made during the J.P. Morgan Healthcare Conference, Hikma has acknowledged that it could be considering an exit strategy for its US generics business after a tough year that has seen forecasts slashed amid heavy pricing and competitive pressures.

Last year, the firm made multiple cuts to its generics guidance as first-half sales dropped by 18%, with the firm’s...